Etanercept in infants: Suberythrodermic, recalcitrant psoriasis in a 22 month-old child successfully treated with etanercept [1]

European Journal of Dermatology

Volumn 17, Issue 3, 2007, Pages 245-

  Fabrizi, Giuseppe ^a,b   Guerriero, Cristina ^c   Pagliarello, Calogero ^b  

^a UNIVERSITY OF MOLISE   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; CORTICOSTEROID; DNA ANTIBODY; ETANERCEPT; ETRETIN;

ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG RESPONSE; EPIDERMIS HYPERPLASIA; HUMAN; LETTER; PRESCHOOL CHILD; PSORIASIS; TREATMENT OUTCOME;

BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOGLOBULIN G; INFANT; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN;

EID: 34249786548     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2007.0159     Document Type: Letter

References (5)

1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352 (18): 1899-1912
2. Mahe E, Bodemer C, Pruszkowski A, Teillac-Hamel D, de Prost Y. Cyclosporine in childhood psoriasis. Arch Dermatol. 2001; 137(11): 1532-3
3. Kress DW. Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis. J Am Acad Dermatol. 2006; 54 (3 Suppl 2): S126-8
4. Hawrot AC, Metry DW, Theos AJ, Levy ML. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol. 2006; 23(1): 67-71.
5. Papoutsaki M, Costanzo A, Massotta A, Gramiccia T, Soda R, Chimenti S. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006; 154 (1): 181-3